Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


For Immunization Managers








Nirsevimab Receipt and Intent for Infants, United States						Print
																Related Pages
										Main Page | NIS Adults 60+ Coverage and Intent | IIS Adult Coverage | Adult Vaccinations Administered | Pregnant Persons Coverage and Intent | IIS Nirsevimab Coverage for InfantsMonthly estimates of receipt and intent for nirsevimab reported by adults females aged 18-49 years with infants under the age of 8 months, females aged 18-49 years who are currently pregnant, and females aged 18-49 years who are currently trying to get pregnant, using data from the National Immunization Survey-Adult COVID Module (NIS-ACM).
The NIS-ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older.
**Figure 5.** Monthly Nirsevimab Receipt and Intent Among Females Aged 18-49 Years Who Have an Infant <8 Months, Are Currently Pregnant, or Are Trying to Get Pregnant, United States*,†. Data Source: National Immunization Survey–Adult COVID Module.
View and Download Data for Fig. 5Note: Confidence Intervals (CI) describe the level of uncertainty around an estimate because a sample was taken. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% confidence interval, if the sampling method is repeated many times, the true value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.
Estimates from the NIS-ACM may differ from estimates based on other data sources, and in addition to random error associated with taking a sample, are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
Estimates of nirsevimab receipt by infants <8 months at time of interview include those who were born shortly before or are entering their first RSV season and do not account for the mother’s RSV vaccination status during pregnancy (Healthcare Providers: RSV Immunization for Children 19 Months and Younger | CDC).
Nirsevimab receipt by the infant or intent for receipt is only asked for female survey respondents aged 18-49 years; estimates may not be representative of households with children <8 months without a female 18-49 years in the household, for which the survey respondent was a female age 50 years or more, or had a male survey respondent aged 18 or more years.
*National estimates include 50 states, Washington D.C., Puerto Rico, and U.S. Virgin Islands.
† Estimates are based on interviews conducted during each specified month; unlike the weekly RSV vaccination coverage estimates, they are not cumulative estimates based on all interviews conducted to date.
							
					
							Last Reviewed:  January 10, 2024						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeImmunization Managers Home
Price Lists & Vaccine Codes
Vaccination Coverageplus icon
ChildVaxView
SchoolVaxView
TeenVaxView
AdultVaxView
FluVaxView
COVIDVaxView
RSVVaxView
Program Contacts
Requirements & Lawsplus icon
State Vaccination Requirementsplus icon
Selected References
HIPAA Overviewplus icon
Access to Patient Records during IQIP & VFC Visits
Perinatal Hepatitis B Prevention
Program Components
Awardee Immunization Websites
Guidelines and Publications


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue